Aqua Bio Technology ASA
Aqua Bio Technology ASA engages in the manufacture and sale of ingredients for cosmetic industry in Norway. It offers Aquabeautine XL, a proprietary ingredient for skincare products; and Spirulysat, an antioxidant and vitamin-boosted spirulina for cosmetic use. The company distributes its products through Internet, stores, and skincare clinics. Aqua Bio Technology ASA was founded in 2000 and is b… Read more
Aqua Bio Technology ASA (ABTEC) - Net Assets
Latest net assets as of June 2024: Nkr113.94 Million NOK
Based on the latest financial reports, Aqua Bio Technology ASA (ABTEC) has net assets worth Nkr113.94 Million NOK as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr291.19 Million) and total liabilities (Nkr177.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr113.94 Million |
| % of Total Assets | 39.13% |
| Annual Growth Rate | 4.8% |
| 5-Year Change | 1071.32% |
| 10-Year Change | N/A |
| Growth Volatility | 1689.25 |
Aqua Bio Technology ASA - Net Assets Trend (2016–2023)
This chart illustrates how Aqua Bio Technology ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aqua Bio Technology ASA (2016–2023)
The table below shows the annual net assets of Aqua Bio Technology ASA from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Nkr85.78 Million | +4510.32% |
| 2022-12-31 | Nkr1.86 Million | -90.05% |
| 2021-12-31 | Nkr18.71 Million | +124.81% |
| 2020-12-31 | Nkr8.32 Million | +13.63% |
| 2019-12-31 | Nkr7.32 Million | +3814.22% |
| 2018-12-31 | Nkr-197.16K | -100.51% |
| 2017-12-31 | Nkr38.53 Million | -37.63% |
| 2016-12-31 | Nkr61.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aqua Bio Technology ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3729.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Nkr118.54 Million | 138.20% |
| Other Components | Nkr35.76 Million | 41.69% |
| Total Equity | Nkr85.78 Million | 100.00% |
Aqua Bio Technology ASA Competitors by Market Cap
The table below lists competitors of Aqua Bio Technology ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sona Topas Tourism Industry
JK:SONA
|
$7.08 Million |
|
UCAL Limited
NSE:UCAL
|
$7.08 Million |
|
Straits Inter Logistics Bhd
KLSE:0080
|
$7.08 Million |
|
Ekopak BV
BR:EKOP
|
$7.09 Million |
|
Vape Holdings Inc
NASDAQ:VAPE
|
$7.08 Million |
|
Focus Dynamics Group Bhd
KLSE:0116
|
$7.07 Million |
|
AddTech Hub Public Company Limited
BK:ADD
|
$7.07 Million |
|
Dextech Medical AB
F:LQ0
|
$7.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aqua Bio Technology ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,860,520 to 85,775,450, a change of 83,914,930 (4510.3%).
- Net loss of 21,023,850 reduced equity.
- Share repurchases of 14,785,200 reduced equity.
- Other factors increased equity by 119,723,980.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-21.02 Million | -24.51% |
| Share Repurchases | Nkr14.79 Million | -17.24% |
| Other Changes | Nkr119.72 Million | +139.58% |
| Total Change | Nkr- | 4510.29% |
Book Value vs Market Value Analysis
This analysis compares Aqua Bio Technology ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.77x to 3.81x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Nkr8.91 | Nkr6.89 | x |
| 2017-12-31 | Nkr5.56 | Nkr6.89 | x |
| 2018-12-31 | Nkr-0.03 | Nkr6.89 | x |
| 2019-12-31 | Nkr0.48 | Nkr6.89 | x |
| 2020-12-31 | Nkr0.45 | Nkr6.89 | x |
| 2021-12-31 | Nkr0.91 | Nkr6.89 | x |
| 2022-12-31 | Nkr0.09 | Nkr6.89 | x |
| 2023-12-31 | Nkr1.81 | Nkr6.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aqua Bio Technology ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -114.22%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 2.77x
- Recent ROE (-24.51%) is above the historical average (-191.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 2.37% | 0.00% | 0.00x | 1.16x | Nkr-4.72 Million |
| 2017 | -41.68% | -1323.00% | 0.02x | 1.27x | Nkr-19.91 Million |
| 2018 | 0.00% | -4380.40% | 0.09x | 0.00x | Nkr-38.45 Million |
| 2019 | -180.47% | -1482.44% | 0.09x | 1.42x | Nkr-13.95 Million |
| 2020 | -176.71% | -3308.86% | 0.03x | 1.95x | Nkr-15.54 Million |
| 2021 | -102.17% | -1225.41% | 0.05x | 1.84x | Nkr-20.98 Million |
| 2022 | -1007.01% | -267.01% | 0.10x | 36.12x | Nkr-18.92 Million |
| 2023 | -24.51% | -114.22% | 0.08x | 2.77x | Nkr-29.60 Million |
Industry Comparison
This section compares Aqua Bio Technology ASA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $73,624,542
- Average return on equity (ROE) among peers: -115.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aqua Bio Technology ASA (ABTEC) | Nkr113.94 Million | 2.37% | 1.56x | $7.08 Million |
| Arctic Bioscience AS (ABS) | $287.28 Million | -11.84% | 0.14x | $3.71 Million |
| Arcticzymes Technologies ASA (AZT) | $68.08 Million | -30.08% | 0.26x | $76.32 Million |
| Circa Group AS (CIRCA) | $41.74 Million | -16.77% | 0.13x | $3.57 Million |
| Circio Holding ASA (CRNA) | $-98.54 Million | 0.00% | 0.00x | $16.90 Million |
| Exact Therapeutics AS (EXTX) | $42.24 Million | -35.10% | 0.23x | $3.19 Million |
| Lytix Biopharma AS (LYTIX) | $107.89 Million | -87.37% | 0.36x | $32.31 Million |
| PCI Biotech Holding ASA (PCIB) | $57.40 Million | -95.98% | 0.11x | $432.13K |
| SoftOx Solutions AS (SOFTX) | $16.01 Million | -444.47% | 3.86x | $12.63 Million |
| Thor Medical ASA (TRMED) | $140.52 Million | -314.06% | 1.11x | $48.68 Million |